Biocon Receives U.S. FDA Approval for Yesintek Autoinjector

Biocon Receives Supplemental U.S. FDA Approval for Yesintek Autoinjector

Biocon Limited has announced that its U.S. subsidiary has received supplemental U.S. FDA approval for Yesintek® (ustekinumab-kfce) single-dose prefilled autoinjectors. The approval expands the available delivery formats for the company's biosimilar ustekinumab product in the United States.

The U.S. FDA initially approved Yesintek® on November 29, 2024. The latest supplemental approval covers the 45 mg/0.5 mL and 90 mg/mL single-dose prefilled autoinjector presentations, providing an additional treatment delivery option for patients and healthcare providers.

Yesintek Therapeutic Indications

Yesintek® is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients aged 6 years and older.

The medicine is also indicated for the treatment of moderately to severely active Crohn's disease and ulcerative colitis in adults.

Yesintek Autoinjector Approval Details

• Product: Yesintek® (ustekinumab-kfce)
• Delivery Format: Single-dose prefilled autoinjector
• Approved Strengths: 45 mg/0.5 mL and 90 mg/mL
• Initial U.S. FDA Approval: November 29, 2024
• Latest Approval: Supplemental U.S. FDA approval for the autoinjector presentation

The new delivery format is intended to provide patients and healthcare providers with another treatment option and support more tailored approaches across different care settings and patient needs.

Strategic Impact for Biocon

The supplemental approval strengthens Biocon's immunology portfolio in the United States and expands the company's range of available Yesintek® presentations.

Biocon Yesintek U.S. FDA Approval Highlights

• Company: Biocon Limited
• Product: Yesintek® (ustekinumab-kfce)
• Approval Authority: U.S. Food and Drug Administration (FDA)
• Approval Type: Supplemental approval
• New Delivery Format: Single-dose prefilled autoinjector
• Approved Strengths: 45 mg/0.5 mL and 90 mg/mL
• Initial FDA Approval: November 29, 2024
• Indications: Plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis
• Age Group: Adults and pediatric patients aged 6 years and older for plaque psoriasis and psoriatic arthritis
• Strategic Significance: Expands Biocon's U.S. immunology portfolio and provides an additional treatment delivery option

What to Watch Next

• Investors may track further updates on the commercial availability of the newly approved Yesintek® autoinjector in the U.S.
• The additional delivery format could support broader adoption of Yesintek® across different patient and care settings.
• Investors may also watch for further regulatory approvals or expanded presentations for Biocon's biosimilar portfolio.
• Further developments in Biocon's U.S. immunology business may remain an area of interest as the company expands its biosimilar portfolio.